Find information on thousands of medical conditions and prescription drugs.

Oxaliplatin

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. more...

Home

OCL

Oncovin

Opium

Oratane

Oretic

Orinase

Oruvail

Ovcon

Ovral

Ovrette

Oxetine

Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Side-effects

Side-effects of oxaliplatin treatment can potentially include:

Neuropathy, specifically including sensitivity to cold and numbness in the hands and feet
Fatigue
Nausea,vomiting, and/or diarrhea
Neutropenia
Hearing loss

In addition, some patients may experience an allergic reaction to platinum-containing drugs.

Read more at Wikipedia.org

• [List your site here Free!]


	Oxaliplatin improves survival in advanced colorectal cancer. (Combination Regimen).(Brief Article) : An article from: Internal Medicine News $5.95	Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer.(Original Article) : An article from: Southern Medical Journal $5.95

	New & approved: FOLFOX, Symbyax.(Rx) : An article from: Family Practice News $5.95


Oxaliplatin Definition Oxaliplatin is an investigational chemotherapy medicine used to treat certain types of cancer by destroying cancerous cells. Oxaliplatin is also known in other countries by i From Gale Encyclopedia of Cancer, by RPh. Nancy J. Beaulieu, BCOP

Reflections on ASCO 2005 I have just returned from the 41st annual meeting of the American Society of Clinical Oncology (ASCO). Twenty-five thousand oncologists converged on ... From Townsend Letter for Doctors and Patients, 8/1/05 by Ralph W. Moss

Chiral Differentiation of DNA Adducts Formed by Enantiomeric Analogues of Antitumor Cisplatin Is Sequence-Dependent ABSTRACT 1,2-GG intrastrand cross-links formed in DNA by the enantiomeric complexes [PtCl^sub 2^(R,R-2,3-diaminobutane (DAB))] and [PtCl^sub 2^(S,S-DAB)] ... From Biophysical Journal, 6/1/05 by Delalande, Olivier

Gpc Biotech/Debiopharm Sign Mhc Ii Antagonists License Pact GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30; NASDAQ: GPCB) and Debiopharm S.A., the independent drug- development company specializing in oncology, endocrinology and niche products, ha From Worldwide Biotech, 2/1/05

New molecular entity: Vesicare®, Yamanouchi/ GlaxoSmithKline Solifenacin: once-daily therapy approved for overactive bladder Solifenacin was approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Dosage. The recommended dose of solifenacin is 5 From Geriatrics, 1/1/05

Losing the War on Cancer An article of extraordinary importance has appeared in Fortune magazine. It is titled "Why We're Losing the War on Cancer." The author, Clifton ... From Townsend Letter for Doctors and Patients, 6/1/04 by Ralph W. Moss

CHEMOTHERAPY FOR PANCREATIC CANCER Pancreatic cancer is the fourth leading cause of cancer death in the United States. It is estimated 31,860 new cases will be diagnosed in the US in 2004.1 ... From Medicine and Health Rhode Island, 5/1/04 by Tsai, James Y

FDA approves Avastin In February, the US Food and Drug Administration (FDA) approved Avastin (bevacizumab) for the treatment of advanced colorectal cancer. Avastin is an ... From Townsend Letter for Doctors and Patients, 5/1/04 by Ralph Moss, W.

Home

Contact

Resources

Exchange Links

ebay